$AstraZeneca PLC(AZN)$ π ±ππ »π »π Έππ ·
πππ AstraZeneca ($AZN): A Pharmaceutical Powerhouse on the Rise! πππ
Kia ora Tiger traders!
AstraZeneca ($AZN) is flexing its pharmaceutical muscle with a remarkable 50% mid-level rebound off $65, and itβs ready to climb higher. The chart signals bullish momentum, and the fundamentals are just as exciting! Letβs break it down. π
π Key Chart Highlights π
π’ 50% Mid-Level Rebound: The stock has found strong support at $65 and is moving upward with confidence.
π’ Resistance Ahead: Watch for $70β$75 as the next challenge, with $80 in sight if momentum holds steady.
π’ π―: $80 aligns with Fibonacci extensions and long-term bullish patterns.
π° Why $AZN Is a π€© Star π Performer
1οΈβ£ Financial Strength: AstraZeneca boasts a gross profit margin of 82.61% and annual revenue of $51.21 billion. Q3 2024 revenue grew 21%, driven by double-digit growth across all therapy areas. Core EPS rose an impressive 27% to $2.08, underpinned by a 19% surge in product sales.
2οΈβ£ Oncology Domination: Oncology revenue hit $16 billion in the first nine months, fuelled by Tagrisso and Enhertu. The oncology pipeline, including Phase 3 readouts like LAURA, could unlock over $5 billion in additional revenue.
3οΈβ£ Regional Performance: The U.S. accounted for 43% of revenue, with emerging markets outside China contributing 14%, surpassing Chinaβs 13%. Alliance revenue grew 50% to $1.5 billion, thanks to Enhertu and Tezspire.
4οΈβ£ Massive R&D Investment: AstraZeneca is making a $3.5 billion investment in U.S. manufacturing and R&D, solidifying its innovation edge and market leadership.
5οΈβ£ Analyst Confidence: With a consensus Strong Buy rating and an average price target of $87.67 (up to $88), analysts predict a potential 29.65% upside from its current price of $67.62.
π Global Strength
AstraZenecaβs global strategy is paying off, with 30% growth in emerging markets outside China. Despite challenges, the company continues investing in China and gaining regulatory approvals across the U.S., Europe, and Asia, driving growth and solidifying its pharmaceutical dominance.
π π Key Levels to Watch
β’ Support: $65 β Holding strong and propelling upward momentum.
β’ Resistance: $70β$75 β A key test for bulls.
β’ π―: $80 β Within reach as the stock rides its bullish wave.
π€ Investor Takeaway
With explosive growth in oncology, robust financial performance, and unmatched global reach, AstraZeneca is making a compelling case for long-term investors and pattern traders alike.
Hey Tiger traders, is $80 just the beginning, or do we break through to new highs? ποΈ Letβs discuss!
TigerGPT, can you crunch the numbers and highlight any hidden opportunities here? π
Happy trading ahead. Cheers, BC! πππ
@Tiger_comments @TigerPM @TigerPicks @Daily_Discussion @TigerStars @TigerObserver @TigerGPT
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
AstraZeneca PLC (AZN) Earnings Analysis
Earnings Data:
AstraZeneca reported strong financial results for Q3 2024. Key highlights include:
Revenue: $51.21 billion, representing a growth of 21% compared to the same period last year.
Gross profit margin: 82.61%
Core EPS (Earnings Per Share): $2.08, a significant increase of 27%.
Product sales saw a surge of 19%.
The company's oncology segment performed exceptionally well, with oncology revenue reaching $16 billion in the first nine months of the year, driven by drugs like Tagrisso and Enhertu.
AstraZeneca's financial strength and overall performance are commendable, with double-digit growth across all therapy areas.
Earnings Call:
Unfortunately, the earnings call transcript for AstraZeneca is not available at the moment.
Key Points of Earnings Report:
The strong financial performance in Q3 2024 was driven by robust demand for the company's medicines and a focus on profitability.
AstraZeneca's global strategy has been successful, with 30% growth in emerging markets outside of China. The company's investments in China and regulatory approvals in the U.S., Europe, and Asia have solidified its position in the pharmaceutical industry.
Relevant Opinion:
According to analysts, AstraZeneca has received a consensus Strong Buy rating, with an average price target of $87.67, implying a potential upside of 29.65% from the current price level. Analysts are optimistic about the company's future prospects.
Disclaimer:The above analysis is based on the available data and should be considered for reference purposes only. It does not constitute investment advice.
nice sharing, BC. i will consider add AZN at $70!
Great article, would you like to share it?
Great article, would you like to share it?
Great article, would you like to share it?
Great article, would you like to share it?